The concentration of CEA and Cyfra 21-1 in patients with non-small cell lung cancer treated with tyrosine kinase inhibitors

Tong Quoc Dong; Ho Thi Long; Nguyen Thi Thu Hien; Doan Vu Nam; Pham Thai Binh; Pham Van Tran

doi:10.54647/pm31142

ISSN: 2995-7060

Volume 5, Number 6 (2021)

Year Launched: 2016

Journal Menu

■ About The Journal

■ Aims & Scope

■ Editorial Board

■ Article Processing Charge

■ Archive

Previous Issues

■ Volume 8, Number 2 (2024)

■ Volume 8, Number 1 (2024)

■ Volume 7, Number 2 (2023)

■ Volume 7, Number 1 (2023)

■ Volume 6, Number 3 (2022)

■ Volume 6, Number 2 (2022)

■ Volume 6, Number 1 (2022)

■ Volume 5, Number 6 (2021)

■ Volume 5, Number 5 (2021)

■ Volume 5, Number 4 (2021)

■ Volume 5, Number 3 (2021)

■ Volume 5, Number 2 (2021)

■ Volume 5, Number 1 (2021)

■ Volume 4, Number 5 (2020)

■ Volume 4, Number 4 (2020)

■ Volume 4, Number 3 (2020)

■ Volume 4, Number 2 (2020)

■ Volume 4, Number 1 (2020)

■ Volume 3, Number 2 (2019)

■ Volume 3, Number 1 (2019)

■ Volume 2, Number 1 (2018)

■ Volume 1, Number 1 (2016)

The concentration of CEA and Cyfra 21-1 in patients with non-small cell lung cancer treated with tyrosine kinase inhibitors

Volume 5, Issue 6, December 2021 | PP. 62-74 | PDF (429 K) | Pub. Date: November 16, 2021
DOI: 10.54647/pm31142 77 Downloads 62040 Views

Author(s)

Tong Quoc Dong, Faculty of postgraduate education, Vietnam Military Medical University, Ha Dong, Ha Noi, Viet Nam

Ho Thi Long, Department of Biochemistry, 103 Military Medical Hospital, Ha Dong, Ha Noi, Viet Nam

Nguyen Thi Thu Hien, Department of Biochemistry, K Tan Trieu Hospital, Thanh Tri, Ha Noi, Viet Nam

Doan Vu Nam, Department of internal medicine, Military Hospital 175, Go Vap, Ho Chi Minh, Viet Nam

Pham Thai Binh, Department of internal medicine, 103 Military Medical Hospital, Ha Dong, Ha Noi, Viet Nam

Pham Van Tran, Department of Biochemistry, 103 Military Medical Hospital, Ha Dong, Ha Noi, Viet Nam

Abstract
Objective: The purpose of this study was to determine CEA and Cyfra 21-1 concentrations in plasma of patients with non- small cell lung cancer before and after three months, six months of treatment with tyrosine kinase inhibitors.
Methods: 400 patients with non-small cell lung cancer were first treated with tyrosine kinase inhibitors (gefitinib or erlotinib). Before and after three months, six months of treatment, the patients were evaluated the clinical symptoms, chest computed tomography and quantified CEA, Cyfra 21-1 concentrations in plasma.
Results: In patients with non-small cell lung cancer, CEA and Cyfra 21-1 data followed an abnormal distribution with the median of 18.94 (range: 1.79 – 1553.0) and a median of 6.52 (range: 1.51 – 590.0), respectively. There was a strong positive correlation between CEA and Cyfra 21-1 concentrations (r = 0.84). CEA and Cyfra 21-1 concentrations decreased after treatment with tyrosine kinase inhibitors but the difference was not statistically significant (p > 0.05).
Conclusions: CEA and Cyfra 21-1 are significant markers for diagnosis and follow-up in patients with non- small cell lung cancer treated with tyrosine kinase inhibitors.

Keywords
CEA, Cyfra 21-1, erlotinib, gefitinib, non- small cell lung cancer

Cite this paper
Tong Quoc Dong, Ho Thi Long, Nguyen Thi Thu Hien, Doan Vu Nam, Pham Thai Binh, Pham Van Tran, The concentration of CEA and Cyfra 21-1 in patients with non-small cell lung cancer treated with tyrosine kinase inhibitors , SCIREA Journal of Medicine. Volume 5, Issue 6, December 2021 | PP. 62-74. 10.54647/pm31142

References

[ 1 ]	Parkin DM. International variation. Oncogene. 2004;23(38):6329-40. doi:10.1038/sj.onc.1207726.
[ 2 ]	Hsieh Y-Y, Fang W-T, Lo Y-W, Chen Y-H, Chien L-N. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non–small-cell lung cancer: A retrospective cohort study in Taiwan. International journal of cancer. 2020;147(4):1107-16. doi:10.1002/ijc.32841.
[ 3 ]	Goss GD, Spaans JN. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. The oncologist. 2016;21(2):205-13. doi:10.1634/theoncologist.2015-0209.
[ 4 ]	Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566-84. doi:10.1007/s00018-008-7440-8.
[ 5 ]	Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Translational lung cancer research. 2012;1(1):5-13. doi:10.3978/j.issn.2218-6751.2011.12.01.
[ 6 ]	Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013;8(8):1069-74. doi:10.1097/JTO.0b013e318294c8e8.
[ 7 ]	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(9):1243-60. doi:10.1097/jto.0000000000000630.
[ 8 ]	Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi L-A, Yap JT et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010;195(3):W221-W8. doi:10.2214/AJR.09.3928.
[ 9 ]	White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7-S15. doi:10.1016/j.amepre.2013.10.029.
[ 10 ]	Kabir Z, Connolly GN, Clancy L. Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland. Ulster Med J. 2008;77(1):31-5.
[ 11 ]	Horeweg N, van der Aalst CM, Thunnissen E, Nackaerts K, Weenink C, Groen HJ et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. American journal of respiratory and critical care medicine. 2013;187(8):848-54. doi:10.1164/rccm.201209-1651OC.
[ 12 ]	Sone K, Oguri T, Nakao M, Kagawa Y, Kurowaka R, Furuta H et al. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy. Anticancer research. 2017;37(2):935-9. doi:10.21873/anticanres.11402.
[ 13 ]	Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung cancer (Amsterdam, Netherlands). 2013;80(1):45-9. doi:10.1016/j.lungcan.2013.01.002.
[ 14 ]	Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery. 2007;32(3):435-9. doi:10.1016/j.ejcts.2007.05.014.
[ 15 ]	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine. 2010;362(25):2380-8. doi:10.1056/NEJMoa0909530.
[ 16 ]	Pang L, Wang J, Jiang Y, Chen L. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer. Exp Ther Med. 2013;6(2):355-60. doi:10.3892/etm.2013.1171.
[ 17 ]	Yang L, Chen X, Li Y, Yang J, Tang L. Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer. Exp Ther Med. 2012;4(2):243-8. doi:10.3892/etm.2012.570.
[ 18 ]	Xu Y, Xu L, Qiu M, Wang J, Zhou Q, Xu L et al. Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer. Scientific Reports. 2015;5(1):9444. doi:10.1038/srep09444.